Details

Autor(en) / Beteiligte

• Lonial, Sagar
• Dimopoulos, Meletios
• Palumbo, Antonio
• White, Darrell
• Grosicki, Sebastian
• Spicka, Ivan
• Walter-Croneck, Adam
• Moreau, Philippe
• Mateos, Maria-Victoria
• Magen, Hila
• Belch, Andrew
• Reece, Donna
• Beksac, Meral
• Spencer, Andrew
• Oakervee, Heather
• Orlowski, Robert Z
• Taniwaki, Masafumi
• Röllig, Christoph
• Einsele, Hermann
• Wu, Ka Lung
• Singhal, Anil
• San-Miguel, Jesus
• Matsumoto, Morio
• Katz, Jessica
• Bleickardt, Eric
• Poulart, Valerie
• Anderson, Kenneth C
• Richardson, Paul

Titel

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Ist Teil von

• The New England journal of medicine, 2015-08, Vol.373 (7), p.621-631

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• The addition of elotuzumab (a monoclonal antibody against SLAMF7) to lenalidomide plus dexamethasone produced a significant increase in progression-free survival as compared with lenalidomide plus dexamethasone alone. Multiple myeloma, a malignant disease of monoclonal plasma cells, has a median overall survival of approximately 5 years. 1 Despite improvements in treatment outcomes with proteasome inhibitors and immunomodulatory drugs, most patients continue to have a relapse, and new treatment approaches are needed. Combination therapy may be key to overcoming drug resistance and improving long-term treatment outcomes. Lenalidomide, an immunomodulatory drug, in combination with dexamethasone is a standard regimen in patients with relapsed or refractory disease. 2 , 3 Three-drug combinations are emerging for patients with previously treated multiple myeloma 3 but may be limited by toxic effects. Agents with new mechanisms of action . . .